Yunyu Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunyu Du has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Fangfang Xu
School of Nursing, Jiangxi Medical College Nanchang University Nanchang China
1 shared publication - Jijin Yang
Department of Burns, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
1 shared publication Li Zhou
Jiangxi Medical Center for Critical Public Health Events, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
1 shared publication- Miaoqing Xia
Department of Thoracic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
1 shared publication Min Wang
Department of Thoracic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
1 shared publicationMin Zhang
Jiangxi Medical Center for Critical Public Health Events, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
1 shared publication
Latest Publications
- 31 March 2026
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
- Vol. 24 (6) , 1228-1237
Evaluation of patient-reported outcome assessment tools for lung cancer: protocol for a systematic review of measurement properties
Objective: The objective of this review will be to appraise the measurement properties of patient-reported outcome assessment tools for lung cancer. Introduction: Patients with lung cancer manifest varying degrees of physical and psychosocial symptoms attributable to disease pathology and treatment-related complications, which significantly impair their quality of life. Although a few patient-reported outcome assessment tools are available for lung cancer, a comprehensive and standardized comparative analysis of their measurement properties is notably lacking. Eligibility criteria: Eligible studies will include patients aged ≥18 years who are diagnosed with lung cancer at any disease stage (I–IV), regardless of treatment modality (eg, surgery, pharmacotherapy, chemotherapy, radiotherapy, neoadjuvant therapy, palliative care). Empirical studies that examine the development or validation of patient-reported outcome measures for patients with lung cancer will be considered if they evaluate at least 1 measurement property (eg, reliability, validity, responsiveness). Methods: The following databases will be searched: PubMed, Web of Science Core Collection, CINAHL (EBSCOhost), Cochrane Library, Embase (Ovid), PsycINFO (Ovid), CNKI, Wanfang, SINOMED, and Weipu. To minimize publication bias and identify unpublished studies, gray literature sources will also be explored, including unpublished agency reports, professional organization websites, and dissertation/thesis databases. Two reviewers will independently conduct study selection and data extraction. Methodological quality appraisal, synthesis of the quality of PROMs, and evidence quality grading will be conducted by 2 reviewers in strict accordance with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) methodology. Review registration: PROSPERO CRD420251028373
- 31 March 2026
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
- Vol. 24 (6) , 1228-1237
Evaluation of patient-reported outcome assessment tools for lung cancer: protocol for a systematic review of measurement properties
Objective: The objective of this review will be to appraise the measurement properties of patient-reported outcome assessment tools for lung cancer. Introduction: Patients with lung cancer manifest varying degrees of physical and psychosocial symptoms attributable to disease pathology and treatment-related complications, which significantly impair their quality of life. Although a few patient-reported outcome assessment tools are available for lung cancer, a comprehensive and standardized comparative analysis of their measurement properties is notably lacking. Eligibility criteria: Eligible studies will include patients aged ≥18 years who are diagnosed with lung cancer at any disease stage (I–IV), regardless of treatment modality (eg, surgery, pharmacotherapy, chemotherapy, radiotherapy, neoadjuvant therapy, palliative care). Empirical studies that examine the development or validation of patient-reported outcome measures for patients with lung cancer will be considered if they evaluate at least 1 measurement property (eg, reliability, validity, responsiveness). Methods: The following databases will be searched: PubMed, Web of Science Core Collection, CINAHL (EBSCOhost), Cochrane Library, Embase (Ovid), PsycINFO (Ovid), CNKI, Wanfang, SINOMED, and Weipu. To minimize publication bias and identify unpublished studies, gray literature sources will also be explored, including unpublished agency reports, professional organization websites, and dissertation/thesis databases. Two reviewers will independently conduct study selection and data extraction. Methodological quality appraisal, synthesis of the quality of PROMs, and evidence quality grading will be conducted by 2 reviewers in strict accordance with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) methodology. Review registration: PROSPERO CRD420251028373
- Open Access
- 19 December 2024
- Published by Elsevier in International Journal of Nursing Sciences
- Vol. 12 (1) , 19-26
Research on equity analysis and forecasting of nursing human resource allocation in Jiangxi Province, China
- 19 December 2024
- Published by Elsevier in International Journal of Nursing Sciences
- Vol. 12 (1) , 19-26
Open AccessResearch on equity analysis and forecasting of nursing human resource allocation in Jiangxi Province, China